Newsroom

Strive to Deliver Breakthroughs

  1. December 09, 2020

    HBM Holdings Limited Announces the Offer Price and Allotment Results of the Global Offering

        This press release is NOT for release, publication, distribution, directly or indirectly, in or into the United States (including its terri...

    View more
  2. November 16, 2020

    Harbour BioMed Will Present Results From Its Phase II Clinical Trial with Tanfanercept (HBM9036) in Patients with Moderate-to-Severe Dry Eye Disease in China at the 25th Congress of Chinese Ophthalmological Society

    The proof-of-concept study demonstrated efficacy, safety, and tolerability of Tanfanercept for the treatment of moderate-to-severe dry eye disease (DED) in Chi...

    View more
  3. September 30, 2020

    Harbour BioMed Announces Dosing of First Patient in Phase II Clinical Studies of Batoclimab (HBM9161) for the Treatment of Myasthenia Gravis and Immune Thrombocytopenia

    Cambridge, MA, Rotterdam, NL, Suzhou, CN— September 30, 2020. Harbour BioMed (HBM), a global, clinical-stage, bio-pharmaceutical company announced today ...

    View more
  4. September 21, 2020

    Harbour BioMed Announces Two China NMPA Clearances for Clinical Trials for Phase I & Combination Therapy of Next Generation Anti-CTLA-4 Antibody for Treatment of Solid Tumors

    Cambridge, MA, Rotterdam, NL, Suzhou, CN – September 21, 2020. Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company ...

    View more
  5. September 11, 2020

    Harbour BioMed and Hualan Genetic Announced Collaboration to Develop Multiple Innovative Antibody Programs

    CAMBRIDGE, Mass., ROTTERDAM, Netherlands, SUZHOU,China and XINXIANG, China, Sept. 11, 2020. Cambridge, MA, Rotterdam, NL, Suzhou Xinxiang, ...

    View more
  6. September 02, 2020

    Harbour BioMed Presented Its Newly Discovered Anti-Human CCR8 Novel Monoclonal Antibodies at the 16th PEGS Boston 2020

    September, 2, 2020, Cambridge, MA, Rotterdam, NL, Shanghai, CN – Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company, pr...

    View more
  7. August 31, 2020

    Harbour BioMed Will Present Its New Platform HBICE™ (Heavy chain only antibody (HCAb) Based Immune Cell Engager) at 16th PEGS Boston Summit

    August, 31, 2020, Shanghai, China – Harbour BioMed, a global, clinical-stage, innovative biopharmaceutical company, today announced that it presented &nb...

    View more
  8. August 24, 2020

    Harbour BioMed Signs Strategic Collaboration Agreement with Vir Biotechnology to Develop Novel Therapies for Immuno-Oncology and Infectious Diseases

    Cambridge, MA, Rotterdam, NL, Suzhou, CN   Harbour BioMed (HBM), a global clinical-stage biopharmaceutical company today announced that it has enter...

    View more
  9. August 21, 2020

    Harbour BioMed Presented Its Newly Discovered BCMA x CD3 Bispecific Antibody at Cell Engager Summit 2020

    HBM’s Bispecific Antibody BCMA X CD3 (HBM7020) has a unique 2+1 format built by the proprietary fully human heavy chain only antibody derived fro...

    View more
  10. August 19, 2020

    Harbour BioMed, Utrecht University, Erasmus Medical Center, Viroclinics-DDL and Kiadis Pharma Announce Collaboration to Develop Monoclonal Antibody, Natural Killer Cell Combination Approach to Treating COVID-19

    Cambridge, MA, Rotterdam, NL, Suzhou CN – August 19, 2020. Harbour BioMed (HBM), and its partners Utrecht University and Erasmus Medical Center, tod...

    View more